John Furey, Imvax executive chair
December 2, 2025 06:30 AM EST
Updated 03:20 PM
FinancingStartupsManufacturing
Imvax shares Phase 2b data for glioblastoma treatment, plans to meet with FDA
Kyle LaHucik
Biotech Correspondent
Imvax, a biotech led by former Spark Therapeutics executives, says its glioblastoma treatment was successful at keeping patients alive about six months longer than standard …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER